Table 3.
Colon 2-weeks | ||||||
---|---|---|---|---|---|---|
Mouse | Human | Function | Vehicle | 61.5 mg/kg | 184.5 mg/kg | 615 mg/kg |
Ccl1 | CCL1 | C-C motif chemokine ligand 1 | 1.00 ± 0.16 | 1.69 ± 0.27 | 4.47 ± 1.17A | 3.61 ± 1.34 |
Cd14 | CXCL1 | C-X-C motif chemokine ligand 1 | 1.00 ± 0.07 | 1.26 ± 0.17 | 1.23 ± 0.11 | 2.81 ± 0.28AB |
Cxcl1 | CD14 | Monocyte differentiation antigen CD14 | 1.00 ± 0.21 | 2.80 ± 0.62A | 2.67 ± 0.54A | 5.57 ± 1.60AB |
Cxcl2** | CXCL2 | C-X-C motif chemokine ligand 2 | 1.00 ± 0.01 | 7.32 ± 1.23A | 97.33 ± 34.23 | 275.7 ± 110.5 |
Fas | FAS | Fas cell surface death receptor | 1.00 ± 0.12 | 1.06 ± 0.12 | 1.46 ± 0.08AB | 0.97 ± 0.09 |
Fasl* | FASLG | Fas ligand | ||||
Icam1 | ICAM1 | Intercellular adhesion molecule 1 | 1.00 ± 0.08 | 1.35 ± 0.09A | 2.29 ± 0.31 AB | 2.76 ± 0.33 AB |
Il1a | IL1A | Interleukin 1 alpha | 1.00 ± 0.25 | 2.14 ± 0.40 | 4.64 ± 0.74AB | 3.51 ± 0.55A |
Il1b | IL1B | Interleukin 1 beta | 1.00 ± 0.14 | 1.57 ± 0.31 | 3.34 ± 0.94 | 3.31 ± 0.95 |
Il2 | IL2 | Interleukin 2 | 1.00 ± 0.11 | 1.25 ± 0.19 | 1.62 ± 0.14A | 1.29 ± 0.27 |
Il4* | IL4 | Interleukin 4 | ||||
Myd88 | MYD88 | MYD88 innate immune signal transduction adaptor | 1.00 ± 0.13 | 1.05 ± 0.04 | 1.11 ± 0.03 | 1.09 ± 0.04 |
Tlr2 | TLR2 | Toll like receptor 2 | 1.00 ± 0.13 | 0.90 ± 0.15 | 1.57 ± 0.16A | 0.94 ± 0.24 |
Tlr4 | TLR4 | Toll like receptor 4 | 1.00 ± 0.18 | 1.12 ± 0.15 | 0.98 ± 0.09 | 1.03 ± 0.11 |
Tnf | TNF | Tumor necrosis factor | 1.00 ± 0.13 | 2.22 ± 0.45A | 2.38 ± 0.39A | 1.80 ± 0.40 |
Data presented at mean fold change from respective vehicle ± SEM (n = 3–6). *, not expressed (cells empty). Gene expression values between vehicle and each dose were compared with a t-test with Welch’s correction, if needed for unequal variances(A, significant comparison), and a one-way ANOVA or Kruskal-Wallis test (if failed equal variance test), followed by a multiple comparisons test, using a Bonferroni or Dunn’s correction, of each dose versus vehicle (**, significant ANOVA or Kruskall-Wallis without significant comparison; B, significant comparison).